<DOC>
	<DOC>NCT01941407</DOC>
	<brief_summary>The efficacy of eribulin is now well known in metastatic breast cancer. Furthermore, a phase III combine study ( chemo + bev)in metastatic first line shown a gain in PFS with no extra toxicities. It could be interesting to explore the combination of bev + eribulin in first line metastatic breast cancer.</brief_summary>
	<brief_title>First Line Metastatic Breast Cancer Treatment (ESMERALDA)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age &gt; 18 ans Patient with metastatic mammary adenocarcinoma Hormone receptors ER and PR positive or negative for HER 2 negative Prior chemotherapy for metastatic disease Previous treatment with eribulin or bevacizumab Presence of symptomatic brain metastases or meningeal</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>